NASDAQ:PXMD PaxMedica (PXMD) Stock Price, News & Analysis $0.0007 +0.00 (+40.00%) As of 07/31/2026 02:17 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About PaxMedica Stock (NASDAQ:PXMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PaxMedica alerts:Sign Up Key Stats Today's Range$0.0007▼$0.000750-Day Range N/A52-Week Range$0.00▼$0.02Volume585 shsAverage Volume4,245 shsMarket Capitalization$7.92 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PaxMedica, Inc. is a clinical‐stage biopharmaceutical company headquartered in Burlingame, California. The company is dedicated to developing novel therapies for central nervous system disorders, with a particular emphasis on addressing unmet needs in autism spectrum disorders, mood disorders and related behavioral conditions. PaxMedica focuses on small-molecule candidates designed to modulate key neural pathways implicated in social and emotional regulation. The company’s lead development program centers on arbaclofen, a proprietary formulation intended to improve social functioning in patients with autism spectrum disorders and associated behavioral challenges. PaxMedica has advanced preclinical and initial clinical work to assess the safety, tolerability and efficacy of this candidate. The company’s research activities leverage collaborations with academic centers and contract research organizations to support its translational pipeline and exploratory biomarker studies. Founded in 2015, PaxMedica has assembled a management team with experience in neuroscience drug development and regulatory strategy. While the company’s primary operations are based in the United States, its clinical trial plans include potential international sites to facilitate patient enrollment. PaxMedica continues to build its pipeline through in-licensing and internal discovery efforts aimed at expanding therapeutic options for patients with challenging neurobehavioral conditions.AI Generated. May Contain Errors. Read More Receive PXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXMD Stock News HeadlinesPaxMedica, Inc. (PXMD) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comStudy Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD PatientsSeptember 23, 2024 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884KSeptember 3, 2024 | msn.comYale Study Unravels Autism, Brain Growth PatternsSeptember 1, 2024 | msn.comPaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | finanznachrichten.dePaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101May 15, 2024 | globenewswire.comPXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024May 13, 2024 | investorplace.comSee More Headlines PXMD Stock Analysis - Frequently Asked Questions How have PXMD shares performed this year? PaxMedica's stock was trading at $0.0001 on January 1st, 2026. Since then, PXMD stock has increased by 600.0% and is now trading at $0.0007. When did PaxMedica's stock split? PaxMedica's stock reverse split on the morning of Tuesday, October 31st 2023.The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did PaxMedica IPO? PaxMedica (PXMD) raised $9 million in an IPO on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO. How do I buy shares of PaxMedica? Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PaxMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that PaxMedica investors own include Pfizer (PFE), PayPal (PYPL), Oracle (ORCL), Arista Networks (ANET), Avino Silver & Gold Mines (ASM) and Corbus Pharmaceuticals (CRBP). Company Calendar Today7/31/2026Next Earnings (Estimated)9/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PXMD CIK1811623 Webwww.paxmedica.com Phone914-987-2876FaxN/AEmployees2Year Founded2018Profitability EPS (Trailing Twelve Months)($6.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-3,167.89% Return on Assets-560.35% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.00Miscellaneous Outstanding Shares11,312,000Free Float11,199,000Market Cap$7.92 thousand OptionableNot Optionable Beta-0.99 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PXMD) was last updated on 8/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PaxMedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
